Login to Your Account



Solid 'Opera' performance for ocrelizumab; Roche plans 2016 filing in MS

By Michael Fitzhugh
Staff Writer

Tuesday, June 30, 2015

Roche AG is planning early 2016 regulatory filings to seek approvals for ocrelizumab, a multiple sclerosis (MS) therapy delivered twice-yearly by I.V. infusion, after two phase III studies showed that it significantly reduced relapses and disability progression vs. Rebif (beta interferon 1a, EMD Serono Inc. and Pfizer Inc.) for people with relapsing MS, the most common form of the disease.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription